MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
18.91
+0.60
+3.28%
Opening 12:46 08/12 EDT
OPEN
18.43
PREV CLOSE
18.31
HIGH
19.22
LOW
18.27
VOLUME
1.45M
TURNOVER
--
52 WEEK HIGH
24.28
52 WEEK LOW
1.330
MARKET CAP
6.47B
P/E (TTM)
-20.2723
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Reaffirms Their Buy Rating on Erasca (ERAS)
TipRanks · 5h ago
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), AnaptysBio (ANAB) and Erasca (ERAS)
TipRanks · 6h ago
Erasca Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6h ago
Erasca Price Target Raised to $22.00/Share From $18.00 by HC Wainwright & Co.
Dow Jones · 6h ago
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Benzinga · 20h ago
Erasca GAAP EPS of -$0.14
Seeking Alpha · 20h ago
Erasca reports Q2 EPS (14c), consensus (11c)
TipRanks · 20h ago
*Erasca 2Q Loss/Shr 14c >ERAS
Dow Jones · 20h ago
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.